Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FSU83
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,122
Award facts
- Contract value 100% obligated
- $17,122.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $17,122.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL autoinjector units. The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the award was made through unrestricted federal procurement competition. DMS Pharmaceutical Group Inc. is the sole awardee with no identified subcontractors on this transaction.
This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical consumable support to Department of Defense healthcare facilities worldwide. The underlying IDC, designated contract SPE2DR and valued at $499,999,999, was awarded to DMS Pharmaceutical Group on November 13, 2025, and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. Through this prime vendor arrangement, DMS Pharmaceutical Group serves as a critical supplier of branded and generic prescription medications, biologics, and specialty pharmaceuticals to support military medical operations globally.
Quick answers
Who was awarded contract SPE2DB26FSU83?
SPE2DB26FSU83 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FSU83 worth?
The government has obligated $17,122 on SPE2DB26FSU83.
Is contract SPE2DB26FSU83 an order under another contract?
Yes. SPE2DB26FSU83 is a delivery order under SPE2DB22D9367, an indefinite delivery contract.
Was contract SPE2DB26FSU83 competed?
The extent of competition for SPE2DB26FSU83 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award